Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 3/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020711 | 0.74 | FGFR1 (0.53) | KCNH2GPR84NPY5RKMT2A | |
| SCHEMBL15020994 | 0.74 | CTSV (0.40) | GHSRCTSVCTSLGPR84NPY5R | |
| SCHEMBL26048631 | 0.72 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL1461108 | 0.71 | GHSR (0.47) | GHSRCTSVCTSLGPR84KMT2A | |
| SCHEMBL15750980 | 0.71 | KDM5A (0.38) | GHSRNPY5RKMT2A | |
| SCHEMBL369110 | 0.70 | CTSV (0.60) | CTSVCTSL | |
| SCHEMBL17426182 | 0.70 | CTSV (0.60) | GHSRCTSVCTSLGPR84 | |
| SCHEMBL30382957 | 0.70 | CTSV (0.60) | CTSVCTSL | |
| SCHEMBL14893206 | 0.70 | HTR1A (0.44) | GHSRKMT2A | |
| SCHEMBL9278047 | 0.70 | GPR84 (0.50) | GHSRCTSVCTSLGPR84KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092444-A1 | DIAZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | ORAI2, ORAI1, RYR2 | KCNH2 49/4885GHSR 2801/4885CTSV 2865/4885 |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | KCNH2 84/4885GHSR 3132/4885CTSV 3273/4885 |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | KCNH2 82/4885GHSR 3135/4885CTSV 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.